1. Report Overview

1.1 Global Respiratory Inhalers Market Overview

1.2 Global Respiratory Inhalers Market Segmentation

1.3 Overview of Findings

1.4 Structure of the Report

1.5 Why You Should Read This Report

1.6 How This Report Delivers

1.7 Key Questions Answered by This Analytical Report

1.8 Who is This Report For?

1.9 Methodology

1.9.1 Primary Research

1.9.2 Secondary Research

1.9.3 Market Evaluation & Forecasting Methodology

1.10 Frequently Asked Questions (FAQ)

1.11 Associated Visiongain Reports

1.12 About Visiongain

2. Introduction to Respiratory Disorders and Therapies

2.1 An Introduction to Respiratory Disorders

2.1.1 Classification of Respiratory Disorders

2.1.2 Asthma

2.1.2.1 Trends in Asthma Prevalence

2.1.2.2 Pathophysiology of Asthma

2.1.2.3 Symptoms of Asthma

2.1.2.4 Treatment of Asthma

2.1.2.5 Guidelines for Asthma Treatment

2.1.2.6 Drug Treatments for Asthma

2.1.3 Chronic Obstructive Pulmonary Disease (COPD)

2.1.3.1 Trends in COPD Prevalence

2.1.3.2 Pathophysiology of COPD

2.1.3.3 Symptoms of COPD

2.1.3.4 Treatment of COPD

2.1.3.5 Drug Treatments for COPD

2.1.3.6 Guidelines for COPD Treatment

2.2 Major Drug Classes in the Treatment of Asthma and COPD

2.2.1 Bronchodilators

2.2.1.1 Beta2-Agonists

2.2.1.2 Anticholinergics

2.2.1.3 Anti-Inflammatory Drugs

2.2.1.4 Corticosteroids

2.2.1.5 Leukotriene Receptor Antagonists

2.2.1.6 Monoclonal Antibodies in the Treatment of Respiratory Disease

2.2.1.7 Combination Drugs

2.2.2 Phases of Clinical Trials

2.2.3 Regulation of Medical Devices

2.2.3.1 The US Approval and Regulation System

2.2.3.2 The EU Approval and Regulation System

2.2.3.3 Post-Marketing Surveillance in the EU



3. Respiratory Inhalers: Global Market Forecast 2018-2028

3.1 The Global Respiratory Inhalers Market in 2018

3.2 Leading Respiratory Inhaler Products

3.3 Leading Companies in the Respiratory Inhalers Market

3.4 Respiratory Inhalers: Trends and Developments

3.4.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers

3.4.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

3.4.3 Telehealth: A Promising Market Trend

3.4.4 Lifecycle Management Strategies to Counter Patent Expiry

3.4.5 Advanced Inhaler Technologies to Counter Generic Erosion

4. Respiratory Inhalers Market by Product Type: Forecast 2018-2028

4.1 Metered Dose Inhalers: Market Forecast 2018-2028

4.2 Dry Powder Inhalers: Market Forecast 2018-2028

4.2.1 Single-Dose DPIs: Market Forecast 2018-2028

4.2.2 Multi-Dose DPIs: Market Forecast 2018-2028

4.3 Nebulizers: Market Forecast 2018-2028

4.3.1 Jet/Compressor Nebulizers: Market Forecast 2018-2028

4.3.2 Ultrasonic Nebulizers: Market Forecast 2018-2028

4.3.3 Vibrating-Mesh Nebulizers: Market Forecast 2018-2028

5. Respiratory Inhalers Market by Indication: Forecast 2018-2028

5.1 Asthma: Market Forecast 2018-2028

5.2 COPD: Market Forecast 2018-2028

5.3 Other Respiratory Diseases: Market Forecast 2018-2028



6. Leading National Markets: Forecast 2018-2028

6.1 Regional Breakdown of the Global Respiratory Inhalers Market

6.2 World Respiratory Inhalers Market Forecast 2018-2028

6.2.1 How will Regional Market Shares Change to 2027?

6.3 The US Respiratory Inhalers Market 2018-2028

6.3.1 The US Respiratory Inhalers Market Forecast 2018-2028

6.3.2 US Respiratory Inhalers Market: Trends and Developments

6.4 EU5 Respiratory Inhalers Market 2018-2028

6.4.1 German Respiratory Inhalers Market Forecast 2018-2028

6.4.2 French Respiratory Inhalers Market Forecast 2018-2028

6.4.3 UK Respiratory Inhalers Market Forecast 2018-2028

6.4.4 Italian Respiratory Inhalers Market Forecast 2018-2028

6.4.5 Spanish Respiratory Inhalers Market Forecast 2018-2028

6.4.6 EU5 Respiratory Inhalers Market: Trends and Developments

6.4.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law

6.4.6.2 France: Social Security Finance Bill 2015

6.4.6.3 UK: Improving Asthma and COPD Patient Outcomes

6.4.6.4 Italy: Austerity Measures Limiting Growth

6.4.6.5 Spain: The Start of Recovery in the Spanish Economy

6.5 Japanese Respiratory Inhalers Market 2018-2028

6.6 BRIC Respiratory Inhalers Market 2018-2028

6.6.1 Chinese Respiratory Inhalers Market Forecast 2018-2028

6.6.2 Indian Respiratory Inhalers Market Forecast 2018-2028

6.6.3 Brazilian Respiratory Inhalers Market Forecast 2018-2028

6.6.4 Russian Respiratory Inhalers Market Forecast 2018-2028

6.7 Mexican Respiratory Inhalers Market Forecast 2018-2028

6.8 Canadian Respiratory Inhalers Market Forecast 2018-2028

7. Leading Companies in the Respiratory Inhalers Market

7.1 GlaxoSmithKline (GSK)

7.1.1 GSK: Product Portfolio

7.1.2 GSK: Financial Overview

7.1.3 Recent Developments

7.1.3.1 US FDA Approval for Labelling changes

7.1.3.2 Japanese Regulatory Approval for Relvar Ellipta

7.1.3.3 FDA and Japan Filing of Triple Drug Therapy

7.1.3.4 FDA Approval for Breo Ellipta to Adult Asthma Patients

7.1.3.5 Launch of Combination Drugs

7.1.3.6 GSK Presented Data on Eosinophil Levels and COPD

7.1.3.7 Approval for Arnuity Ellipta

7.1.3.8 Approval for Incruse Ellipta

7.1.3.9 GSK: Products in Development

7.2 AstraZeneca

7.2.1 AstraZeneca: Product Portfolio

7.2.2 AstraZeneca: Financial Overview

7.2.3 Recent Developments

7.2.3.1 Japan Approval for Fasenra (benralizumab)

7.2.3.2 EU Approval for Fasenra (benralizumab)

7.2.3.3 FDA Approval for Fasenra (benralizumab)

7.2.3.4 AstraZeneca and Circassia enter strategic collaboration

7.2.3.5 FDA Approval for Symbicort in Paediatric Patients

7.2.3.6 Charity-Industry Collaboration

7.2.3.7 FDA approval for Bevespi Aerosphere

7.2.3.8 AstraZeneca Acquired Right to Actavis’ Branded Respiratory Portfolio in US and Canada

7.2.3.9 AstraZeneca Acquired Almirall’s Respiratory Portfolio

7.2.3.10 Takeda Respiratory Portfolio Acquisition

7.2.4 AstraZeneca: Products in Development

7.3 Boehringer Ingelheim

7.3.1 Boehringer Ingelheim: Product Portfolio

7.3.2 Boehringer Ingelheim: Financial Overview

7.3.3 Recent Developments

7.3.3.1 Expanded indication for SPIRIVA Respimat in EU

7.3.3.2 Collaboration with Kaohsiung Medical University

7.3.3.3 Collaboration with Weill Cornell Medicine

7.3.3.4 Collaboration with Qualcomm Incorporated

7.3.3.5 Partnership with Propeller Health

7.3.3.6 FDA Approval for Spiriva Respimat

7.3.3.7 Regulatory Approval for Stiolto Respimat

7.3.3.8 Expansion of Respimat Manufacturing Capacity

7.3.3.9 FDA Approval for Stiverdi Respimat

7.3.4 Boehringer Ingelheim: Respiratory Product Pipeline

7.4 Merck & Co. (Merck)

7.4.1 Merck: Product Portfolio

7.4.2 Merck: Financial Overview

7.4.3 Recent Developments

7.4.4 Merck: Products in Development

7.5 Teva

7.5.1 Teva: Product Portfolio

7.5.2 Teva: Financial Overview

7.5.3 Teva: Recent Developments

7.5.3.1 US launch of QVAR REDIHALER

7.5.3.2 FDA Approval for RespiClick

7.5.3.3 European Approval for Aerivio Spiromax

7.5.3.4 FDA Approval for ProAir RespiClick (albuterol sulfate)

7.5.3.5 Acquisition of Gecko Health Innovations

7.5.3.6 Partnership with IBM Watson Health

7.5.4 Teva: Products in Development

7.6 Novartis International AG

7.6.1 Novartis: Product Portfolio

7.6.2 Novartis: Financial Overview

7.6.3 Novartis: Recent Developments

7.6.3.1 Partnership with Propeller Health

7.6.3.2 Exclusive License Agreement with Sunovion Pharma

7.6.3.3 Partnership with Qualcomm Incorporated

7.6.3.4 FDA Approval for Utibron Neohaler

7.6.3.5 Novartis Presented Data on Ultibro and Seebri

7.6.3.6 Pfizer Promotes Two Novartis COPD drugs in the UK

7.6.4 Novartis: Products Under Development

7.7 Chiesi Farmaceutici S.p.A.

7.7.1 Chiesi: Product Portfolio

7.7.2 Chiesi: Financial Overview

7.7.3 Chiesi: Recent Developments

7.7.3.1 Approvals for Trimbow

7.7.3.2 Regulatory Approval for NEXThaler

7.7.3.3 Chiesi: Products Under Development

8. Qualitative Analysis of Respiratory Inhalers Market

8.1 Market Dynamics

8.1.1 Drivers and Opportunities

8.1.1.1 Growing Burden of Respiratory Diseases

8.1.1.2 Smart Inhalers Provide High Growth Opportunities

8.1.1.3 Triple Drug Therapy for COPD To Offer New Revenue Prospects

8.1.2 Restraints and Challenges

8.1.2.1 Patent Expiry and Generic Competition

8.1.2.2 High Cost Impeding Growth of DPIs In Cost-Sensitive Markets

8.2 Porter’s Five Forces Analysis of the Respiratory Inhalers Market

8.2.1 Rivalry among Competitors [Medium]

8.2.2 Threat of New Entrants [Medium]

8.2.3 Power of Suppliers [Medium]

8.2.4 Power of Buyers [High]

8.2.5 Threat of Substitutes [Low]

9. Conclusions

9.1 Respiratory Inhalers: A Maturing Market

9.2 The Global Respiratory Inhalers Market, 2016 - 2028

9.3 Leading Respiratory Inhalers

9.4 Leading Respiratory Inhaler Companies

9.5 Leading Regional and National Markets

9.6 Global Respiratory Inhalers Market Forecast, 2018-2028

9.7 The Future of Respiratory Inhalers Market

Appendices

Glossary

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Figures

Figure 1.1 Ageing Population Estimates 2010 - 2050

Figure 1.2 Global Respiratory Inhalers: Market Segmentation

Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016

Figure 2.2 Summary of GOLD Guidance for COPD Treatment

Figure 3.1 World Respiratory Inhalers Market: Market Shares (%) for Major National Markets

Figure 3.2 Top 5 Respiratory Inhalers: Market Shares (%), 2016

Figure 4.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028

Figure 4.2 Metered Dose Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028

Figure 4.4 Single-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 4.5 Multi-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 4.6 World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Figure 4.7 World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Figure 4.8 World Vibrating-Mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Figure 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Disease Indication, 2016-2028

Figure 5.2 World Asthma Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 5.3 World COPD Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 5.4 World Respiratory Inhalers Market for Other Diseases, Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.1 Respiratory Inhalers Market: Revenues ($m) by Region, 2018

Figure 6.2 World Respiratory Inhalers Market: Market Shares (%) by Region, 2018

Figure 6.3 World Respiratory Inhalers Market Forecast: Revenues ($m) by Region, 2016-2028

Figure 6.4 World Respiratory Inhalers Market: Market Shares (%) by Region, 2018

Figure 6.5 World Respiratory Inhalers Market: Market Shares (%) by Region, 2023

Figure 6.6 World Respiratory Inhalers Market: Market Shares (%) by Region, 2028

Figure 6.7 US Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.8 EU5 Respiratory Inhalers Market Forecast: Revenues ($m) by National Market, 2016-2028

Figure 6.9 German Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.10 French Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.11 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%), 2016-2028

Figure 6.12 Italian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.13 Spanish Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.14 Japanese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.15 BRIC Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.16 Chinese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.17 Indian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.18 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.19 Russian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.20 Mexican Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 6.21 Canadian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028

Figure 7.1 GSK: Major Respiratory Inhalers Revenue ($m), 2017

Figure 7.2 GSK: Major Respiratory Inhalers Revenue Share (%) by Product, 2017

Figure 7.3 GSK: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028

Figure 7.4 AstraZeneca: Major Respiratory Inhalers Revenue ($m), 2017

Figure 7.5 AstraZeneca: Major Respiratory Inhalers Revenue Share (%), by Product, 2017

Figure 7.6 AstraZeneca: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028

Figure 7.7 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), 2017

Figure 7.8 Boehringer Ingelheim: Major Respiratory Inhalers Revenue Share (%), by Product, 2017

Figure 7.9 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028

Figure 7.10 Merck: Major Respiratory Inhalers Revenue ($m), 2017

Figure 7.11 Merck: Major Respiratory Inhalers Revenue Share (%) by Product, 2017

Figure 7.12 Merck: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028

Figure 7.13 Teva: Major Respiratory Inhalers Revenue ($m), 2017

Figure 7.14 Teva: Major Respiratory Inhalers Revenue Share (%) by Product, 2017

Figure 7.15 Teva: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028

Figure 7.16 Novartis: Major Respiratory Inhalers Revenue ($m), 2017

Figure 7.17 Novartis: Major Respiratory Inhalers Revenue Share (%), by Product, 2017

Figure 7.18 Novartis: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028

Figure 7.19 Chiesi: Foster Inhaler Revenue ($m) and AGR (%), 2016-2028

Figure 8.1 Porter’s Five Forces Analysis of the Respiratory Inhalers Market, 2016-2028

Figure 9.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028

List of Tables

Table 2.1 Classification of Respiratory Diseases

Table 2.2 Clinical Trial Phases

Table 3.1 Top 5 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2017

Table 4.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Product Type, 2016-2028

Table 4.2 World Metered Dose Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028

Table 4.4 Types of Marketed Breezhaler Devices

Table 4.5 Single-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.6 Multi-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.7 World Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Type, 2016-2028

Table 4.8 World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.9 World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.10 World Vibrating-Mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Disease Indication, 2016-2028

Table 5.2 World Asthma Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.3 World COPD Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.4 World Respiratory Inhalers Market for Other Diseases, Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.1 World Respiratory Inhalers Market: Revenues ($m) and Market Shares (%) by Region, 2018

Table 6.2 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2028

Table 6.3 Market Shares (%) of Leading Regional Respiratory Inhalers Markets, 2016, 2022 and 2027

Table 6.4 US Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.5 EU5 Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2028

Table 6.6 German Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.7 French Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.8 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.9 Italian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.10 Spanish Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.11 Japanese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.12 BRIC Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.13 Chinese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.14 Indian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.15 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.16 Russian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.17 Mexican Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.18 Canadian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.1 GSK: Overview, 2017

Table 7.2 GSK: Respiratory Inhaler Products

Table 7.3 GSK: Major Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type,2016-2028

Table 7.4 GSK: Respiratory Therapies Pipeline, 2017

Table 7.5 AstraZeneca: Overview, 2017

Table 7.6 AstraZeneca: Respiratory Inhaler Products

Table 7.7 AstraZeneca: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028

Table 7.8 AstraZeneca: Respiratory Therapies Pipeline, 2017

Table 7.9 Boehringer Ingelheim: Overview, 2017

Table 7.10 Boehringer Ingelheim: Respiratory Inhaler Products

Table 7.11 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028

Table 7.12 Merck: Overview, 2017

Table 7.13 Merck: Respiratory Inhaler Products

Table 7.14 Merck: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028

Table 7.15 Teva: Overview, 2017

Table 7.16 Teva: Respiratory Inhaler Products

Table 7.17 Teva: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028

Table 7.18 Teva: Respiratory Product Pipeline,2017

Table 7.19 Novartis: Overview, 2017

Table 7.20 Novartis: Respiratory Inhaler Products

Table 7.21 Novartis: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028

Table 7.22 Novartis: Respiratory Product Pipeline, 2016

Table 7.23 Chiesi: Overview, 2017

Table 7.24 Chiesi: Respiratory Inhaler Products

Table 7.25 Chiesi: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028

Table 9.1 Top 10 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2017